Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 7, 2010, Pages 1266-1275

  Zhou, Xin Xin ^a   Ji, Feng ^a   Zhao, Jing Li ^a   Cheng, Lin Fang ^a   Xu, Cheng Fu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

gastric cancer; human epidermal growth factor receptor 2; immunotoxin; ricin A chain; target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOTOXIN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; P185 EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY PLUS RICIN A; PROPIDIUM IODIDE; PROTEIN P185; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY HER 2 RICIN A CONJUGATE; RICIN A; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC ANTIMETABOLITE; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; RELA PROTEIN, HUMAN; RICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; WESTERN BLOTTING; ANTIPROLIFERATIVE ACTIVITY; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; GASTRIC CANCER CELL LINE; MTT ASSAY; PROPIDIUM IODIDE ASSAY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, ERBB-2; RICIN; STOMACH NEOPLASMS; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954006805     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06287.x     Document Type: Article

References (37)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J. Clin. Epidemiol. 2003 56 : 1 9.
2. Kremser R, Obrist P, Spizzo G et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003 442 : 322 328.
3. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol. Neoplasia 2001 6 : 393 406.
4. Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005 16 : 273 278.
5. Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006 15 : 65 71.
6. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2009 40 : 769 777.
7. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 369 : 29 36.
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl. J. Med. 2005 353 : 1673 1684.
9. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2- positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006 11 : 318 324.
10. Boyer CM, Pusztai L, Wiener JR et al. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int. J. Cancer 1999 82 : 525 531.
11. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin. Cancer Res. 1999 5 : 865 874.
12. von Minckwitz G, Harder S, Hövelmann S et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005 7 : 617 626.
13. Polito L, Bolognesi A, Tazzari PL et al. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 2004 18 : 1215 1222.
14. HER-2 ricin a chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin. Cancer Res. 2000 6 : 3334 3341.
15. Martínez-Torrecuadrada JL, Cheung LH, López-Serra P et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol. Cancer Ther. 2008 7 : 862 873.
16. Rao PV, Jayaraj R, Bhaskar AS. Mechanism of ricin-induced apoptosis in human cervical cancer cells. Biochem. Pharmacol. 2005 69 : 855 865.
17. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res. 2000 258 : 417 424.
18. Kang MJ, Ryu BK, Lee MG et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 2008 135 : 2030 2042.
19. van Rees BP, Saukkonen K, Ristimäki A et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J. Pathol. 2002 196 : 171 179.
20. Karin M, Lin A. NF-κB at the crossroad of life and death. Nat. Immunol. 2002 3 : 221 227.
21. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 62 : 6323 6328.
22. Carlsson J, Drevin H, Axen R. Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio) propionate, a new heterobifunctional reagent. Biochem. J. 1978 173 : 723 737.
23. Nanda GS, Sun FX, Hofmann GA. Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res. 1998 18 : 999 1004.
24. Zhang K, Chow PK. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin. Cancer Res. 2004 10 : 5226 5232.
25. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int. J. Oncol. 2005 27 : 681 685.
26. Rebischung C, Barnoud R, Stéfani L, Faucheron JL, Mousseau M. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the cerbB-2 protein. Gastric Cancer 2005 8 : 249 252.
27. Kim SY, Kim HP, Kim YJ et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol. 2008 32 : 89 95.
28. Shinohara H, Morita S, Kawai M et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J. Surg. Res. 2002 102 : 169 177.
29. Green DR, Evan GI. A matter of life and death. Cancer Cells 2002 1 : 19 30.
30. Lim JW, Kim H, Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab. Invest. 2001 81 : 349 360.
31. Wu H, Li W, Wang T, Shu Y, Liu P. Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells. Biomed. Pharmacother. 2008 62 : 659 666.
32. Tamatani T, Azuma M, Ashida Y et al. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gammairradiation- and 5-FU-induced production of IL-6 and IL-8. Int. J. Cancer 2004 108 : 912 921.
33. Yamanaka N, Sasaki N, Tasaki A. Nuclear factor-kappa B p65 is a prognostic indicator in gastric carcinoma. Anticancer Res. 2004 24 : 1071 1075.
34. Leung WK, To KF, Ng YP et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer 2001 84 : 335 339.
35. Chen CN, Hsieh FJ, Cheng YM, Chang KJ, Lee PH. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. J. Surg. Oncol. 2006 94 : 226 233.
36. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J. Biol. Chem. 2002 277 : 18649 18657.
37. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999 18 : 305 314.